PLYX

$5.63

Post-MarketAs of Mar 17, 8:00 PM UTC

Polaryx Therapeutics, Inc., clinical-stage biotechnology company, develops small molecule and gene therapy treatments for lysosomal storage disorders.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Intraday

Custom Range:
to
No data available for this range. Intraday data may be limited by the exchange.

Recent News

TipRanks
Feb 4, 2026

Polaryx to present late-breaker data related to Soteria ahead of trial

Polaryx (PLYX) Therapeutics announces it will be presenting a late-breaking abstract on new data for PLX-200, an investigational therapy for the treatment of Krabbe disease at the 22nd Annual WORLDSymposium, held February 2-6, 2026 in San Diego, Calif. These data support the continued advancement on progressing the launch of the Soteria trial, a Phase 2, open-label, single arm trial intended to assess the safety, tolerability, and clinical activity of PLX-200, in CLN2, CLN3, Krabbe disease, and

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.